Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
38 hedge funds and large institutions have $38.9M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 10 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
7% less funds holding
Funds holding: 41 → 38 (-3)
16% less capital invested
Capital invested by funds: $46.3M → $38.9M (-$7.45M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GF
Gabelli Funds
Rye,
New York
|
+$2.02M |
| 2 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$1.85M |
| 3 |
NM
Newtyn Management
New York
|
+$1.58M |
| 4 |
Millennium Management
New York
|
+$1.37M |
| 5 |
Walleye Capital
New York
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAS
VR Advisory Services
Camana Bay, Grand Cayman,
Cayman Islands
|
-$3.05M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.35M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.92M |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$935K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$691K |
CYT Hedge Fund Activity: Q4 2023 in Review
38 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q4 2023, worth a combined $38.9M — down 16% from $46.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CYT and 8 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 12 added.
The largest buyer was Gabelli Funds, adding an estimated $2.02M. The largest seller was VR Advisory Services, exiting entirely with an estimated $3.05M sold.
- 38 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q4 2023, down from 41 in Q3 2023.
- Funds reported $38.9M of Cyteir Therapeutics, Inc. Common Stock stock for Q4 2023, down 16% quarter-over-quarter.
- 8 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q4 2023 and 10 closed out, a net change of -2 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q4 2023 was Gabelli Funds, an estimated $2.02M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q4 2023 was VR Advisory Services, an estimated $3.05M sold.
Based on aggregated 13F filings for Q4 2023.